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Results: Immun histochemistry on control 
and IBD tissue in humans with α-periostin
Experimental design Outlook
Fig.  1:  Intestinal  Periostin  expression in  IBD patients  A and 
control patients B. Note the different pattern of expression and 
the  increased intensity.  A similar  pattern  can be  observed in 
DSS induced  murine tissue.
The expression of CCR5 in each group. (A) Strong positive expression 
of CCR5 in active Crohns Disease CD; (C) Weakly positive expression 
of CCR5 in remissive CD; (D) Weakly positive expression of CCR5 in 
the control; (F) Negative expression of CCR5 in the control. (Taken 
from Ye et al. [4] 
Chemical induction of IBD in mice using different agents and 
different  conditions.  Disease  severity  and  progression  will  be 
closely monitored.
1.  Once the new variants have been confirmed to be active in the IBD setting 
the possibility to use live microbes expressing the antagonist will be tested 
in-vivo.
2.  As absence of Periostin has an impact on IBD severity and progression 
inhibition of periostin-signalling as potential  route for treatment of IBD 
will be exploited.
3.  In case absence of Periostin has no impact on CCR5 expression (expected 
to lower expression) inhibition of periostin-signalling in combination with 
CCR5 blockage will be exploited as potential route for treatment of IBD.
Results: Immunohistochemistry on different 
patients using  α-CCR5
	
Mouse as a model
CCR5 & CCL5
20  distinct  chemokine  receptors  (CCRs)  are  currently  known  in 
humans.  They  are  characterized  by  a  7-transmembrane  (7TM) 
structure and couples to G-protein for signal transduction within the 
expressing cell, making them members of a large protein family of G 
protein-coupled receptors. Following interaction with their specific 
chemokine  ligands,  the  chemokine  receptors  trigger  a  flux  in 
intracellular calcium (Ca2+) ions that causes cell responses, including 
chemotaxis  that  traffics  the  cell  to  a  desired  location  within  the 
organism. At least 10 types of CCRs can be detected in the gut and 
might be associated with IBD. Studies have shown that the CCR5 
antagonists  could  alleviate  the  pathological  changes  and  improve 
clinical symptoms by reducing leukocyte infiltration in experimental 
models of IBD.
Hypothesis
Periostin  has  been  shown  to  be  involved  in  a  variety  of 
inflammatory  processes  and  is  in  general  exaccerbating  the 
inflammation. Absence of Periostin in the IBD setting is protective 
as  we  and  others  have  shown.  CCR5 antagonists  are  known to 
alleviate the inflammatory process and thus negative side-effects. 
Whether Periostin and CCR5 sigalling is happening via the same 
route will be tested here. 
Additionally the new variants of CCL5 will be tested in the IBD 
setting. It is expected that these molecules are highly active in-vivo 
and will be very potent.
Our expectation is that the absence of Periostin has an impact on 
MMPs  and  chemokine  receptors  and  thus  would  open  novel 
options for treatment by inhibiting these activities. In the second 
part of the project we will test the CCR5 antagonist as chemically 
synthesized protein [5] in-vivo in the DSS and other IBD models.  
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The incidence of IBD is rising all over the world and is affecting 1 in 
4000  people  in  Europe  and  1  in  16.000  in  Asia.  [1]  Well-
documented,  reliable  numbers  for  Kazakhstan  are  currently  not 
available  but  observations  from  local  physicians  (personal 
communication) suggest that numbers might be significantly higher 
than suggested by the literature. The matricellular protein Periostin 
has recently been shown to be involved in IBD [2] (and our own 
unpublished data). In a chemically induced murine model (dextrane 
sulfate sodium DSS) it mediates intestinal inflammation through the 
activation  of  NF-κB signaling,  which  suggests  that  periostin  is  a 
potential  therapeutic  target  for  inflammatory  bowel  disease  [2]. 
CCL5,  also  know  as  RANTES,  is  a  chemokine  shown  to  be 
interacting with the G protein-coupled receptors CCR1, CCR3 and 
CCR5 [3]. In a recent study it could be shown that CCR5 expression 
correlates with the infiltration of inflammatory cells into the lamina 
propria of IBD patients [4].
Periostin  is  a  matricellular  protein  originally  isolated  from 
osteoblasts  and  found  to  be  preferentially  expressed  in  the 
periosteum [5, 6]. Periostin contains an N-terminal secretory signal 
peptide,  followed  by  a  cysteine-rich  domain,  four  internal 
homologous repeats, and a C-terminal hydrophilic domain. The four 
internal  repeats  exhibit  homology  to  the  axon  guidance  protein 
fasciclin I that is involved in the development of nervous system in 
invertebrates and were thus named fasciclin domains. 
Structure/Function of periostin
Modified from: http://www.shino-test.co.jp/en/product/periostin/about.html
Vangelista and his team 
showed  in  a  recent 
report  that  by  rational 
CCL5 mutagenesis they 
were able to generate an 
agonist  and  antagonist 
of very high activity [5]. 
Modified from The Expanding Therapeutic Perspective of CCR5 Blockade: Vangelista and Vento, Front Immunol. doi:  10.3389/fimmu.2017.01981
Disruption  of  the  intestinal  epithelial 
barrier  and  thereby  the  entry  of 
luminal  bacteria  or  bacterial  antigens 
into  the  mucosa  has  been  clearly 
established as a disease mechanism in 
enterocolitis by the fact that intestinal 
inflammation  can  be  more  easily 
induced or may occur spontaneously in 
numerous murine models characterized 
by molecular abnormalities that cause 
massive barrier loss.
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